130 related articles for article (PubMed ID: 8136318)
21. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
[TBL] [Abstract][Full Text] [Related]
22. [Autoantibodies in vitiligo. Clinical significance].
Morgan M; Castells A; Ramírez A
Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
[TBL] [Abstract][Full Text] [Related]
23. Histamine effect on melanocyte proliferation and vitiliginous keratinocyte survival.
Kim NH; Lee AY
Exp Dermatol; 2010 Dec; 19(12):1073-9. PubMed ID: 21054556
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis.
Howanitz N; Nordlund JL; Lerner AB; Bystryn JC
Arch Dermatol; 1981 Nov; 117(11):705-8. PubMed ID: 7316530
[TBL] [Abstract][Full Text] [Related]
25. Repigmentation in vitiligo universalis: role of melanocyte density, disease duration, and melanocytic reservoir.
Dogra S; Kumar B
Dermatol Online J; 2005 Dec; 11(3):30. PubMed ID: 16409926
[TBL] [Abstract][Full Text] [Related]
26. [Melanocyte antibodies in idiopathic vitiligo (author's transl)].
Höfs T; Zugehör M; Morenz J
Dermatol Monatsschr; 1981 Nov; 167(11):685-92. PubMed ID: 7044847
[No Abstract] [Full Text] [Related]
27. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo.
Austin LM; Boissy RE
Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691
[TBL] [Abstract][Full Text] [Related]
28. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?
Gauthier Y; Cario Andre M; Taïeb A
Pigment Cell Res; 2003 Aug; 16(4):322-32. PubMed ID: 12859615
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo.
Durham-Pierre DG; Walters CS; Halder RM; Pham HN; Vanderpool EA
J Am Acad Dermatol; 1995 Jul; 33(1):26-30. PubMed ID: 7601942
[TBL] [Abstract][Full Text] [Related]
30. Melanocyte-specific CD49a
Yokoi K; Watanabe R; Kume M; Yamane S; Tanaka A; Fujimoto M; Tanemura A
J Dermatol; 2023 May; 50(5):710-714. PubMed ID: 36514908
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo.
van den Wijngaard RM; Asghar SS; Pijnenborg AC; Tigges AJ; Westerhof W; Das PK
Br J Dermatol; 2002 Jan; 146(1):80-7. PubMed ID: 11841370
[TBL] [Abstract][Full Text] [Related]
32. Role of oxidative stress and autoimmunity in onset and progression of vitiligo.
Laddha NC; Dwivedi M; Mansuri MS; Singh M; Gani AR; Yeola AP; Panchal VN; Khan F; Dave DJ; Patel A; Madhavan SE; Gupta R; Marfatia Z; Marfatia YS; Begum R
Exp Dermatol; 2014 May; 23(5):352-3. PubMed ID: 24628992
[TBL] [Abstract][Full Text] [Related]
33. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo.
Austin LM; Boissy RE; Jacobson BS; Smyth JR
Clin Immunol Immunopathol; 1992 Aug; 64(2):112-20. PubMed ID: 1643744
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients.
Li Y; Yang M; Zhang R; Liu W; Zhang K; Wen W; Yi L; Wang Q; Hao M; Yang H; Chang J; Li J
Immunol Res; 2016 Dec; 64(5-6):1150-1156. PubMed ID: 27417998
[TBL] [Abstract][Full Text] [Related]
35. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation.
Naughton GK; Eisinger M; Bystryn JC
J Invest Dermatol; 1983 Dec; 81(6):540-2. PubMed ID: 6196421
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
37. Melanocyte-specific cell mediated immune response in vitiliginous Smyth line chickens.
Wang X; Erf GF
J Autoimmun; 2003 Sep; 21(2):149-60. PubMed ID: 12935784
[TBL] [Abstract][Full Text] [Related]
38. Immune mechanisms in vitiligo.
Bystryn JC
Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
[TBL] [Abstract][Full Text] [Related]
40. Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors.
Goldstein NB; Koster MI; Hoaglin LG; Spoelstra NS; Kechris KJ; Robinson SE; Robinson WA; Roop DR; Norris DA; Birlea SA
J Invest Dermatol; 2015 Aug; 135(8):2068-2076. PubMed ID: 25822579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
